GLP-1RAs Linked to Reduced Uveitis Risk

A large cohort study suggests uveitis risk is lower in patients taking GLP-1 receptor agonists, compared to other antihyperglycemic drugs.

1

GLP-1 receptor agonists (GLP-1RAs) are linked to a lower incidence of noninfectious uveitis compared to other antihyperglycemic drugs.
2

The study analyzed records from 516,052 patients, revealing a risk ratio of 0.48 for uveitis in GLP-1RA users.
3

Subanalyses showed that GLP-1RAs reduced uveitis risk in both type 2 diabetes patients (RR 0.54) and non-diabetic patients (RR 0.52).
4

Compared to metformin and insulin, GLP-1RAs were associated with greater reductions in uveitis risk, although slightly higher than SGLT2 inhibitors.
5

The findings suggest potential anti-inflammatory benefits of GLP-1RAs, warranting further investigation into their role in ocular inflammatory diseases.

1